Investigational drug · Phase 2
QLS1304
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced ER+/HER2- Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "QLS1304"
First trial start
2026
Jan 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS1304", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced ER+/HER2- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS1304" as an intervention, largest first.
Qilu Pharmaceutical Co., Ltd.Industry
NCT07235176 · 300 participants (planned) · Start Jan 16, 2026 · Primary completion Nov 2, 2028
Drug: QLS1304 tablet+Fulvestrant or QLC1401; QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i · For: Advanced ER+/HER2- Breast Cancer
Sites: Shanghai, China
- Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant TumorsRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06823609 · 180 participants (planned) · Start Mar 6, 2025 · Primary completion Nov 2026
Drug: QLS1304 tablet · For: Advanced Malignant Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced ER+/HER2- Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.